[Pe-21] English Poster Session 21 Peripheral neuropathy 02

[Pe-21-12] Global Open-label Extension: 24-month Data of Patisiran in Patients with hATTR Amyloidosis

^○Mitsuharu Ueda¹, D Adams², A González-duarte³, E Mauricio⁴, T Brannagan⁵, T Coelho⁶, J Wixner⁷, H Schmidt⁸, E Berber⁹, Mt Sweetser¹⁰, Mt White¹⁰, Jj Wang⁹, M Polydefkis¹¹ (1.Kumamoto University, Kumamoto, Japan (presenting on behalf of the authors), Japan, 2.National Reference Center for FAP (NNERF)/ APHP/ INSERM U 1195/ CHU Bicêtre, Le Kremlin Bicêtre, France, 3.Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico City, Mexico, 4.Mayo Clinic, Jacksonville, FL, USA, 5.Department of Neurology, Columbia University, New York City, NY, USA, 6.Hospital de Santo António, Porto, Portugal, 7.Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden, 8.University Hospital Muenster, Muenster, Germany, 9.Former affiliation of Alnylam Pharmaceuticals, Cambridge, USA, 10.Alnylam Pharmaceuticals, Cambridge, USA, 11.Johns Hopkins University, Baltimore, USA)